Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 163 | 2023 | 878 | 22.420 |
Why?
|
Transplantation Conditioning | 91 | 2023 | 373 | 14.420 |
Why?
|
Graft vs Host Disease | 75 | 2023 | 364 | 13.110 |
Why?
|
Cord Blood Stem Cell Transplantation | 27 | 2023 | 93 | 11.090 |
Why?
|
Hematologic Neoplasms | 35 | 2023 | 329 | 7.080 |
Why?
|
Transplantation, Homologous | 108 | 2023 | 996 | 7.080 |
Why?
|
Lymphoma | 28 | 2021 | 262 | 5.720 |
Why?
|
Lymphoma, Non-Hodgkin | 33 | 2024 | 261 | 5.210 |
Why?
|
Bone Marrow Transplantation | 47 | 2019 | 285 | 4.680 |
Why?
|
Leukemia, Myeloid, Acute | 25 | 2023 | 755 | 4.060 |
Why?
|
Lymphoma, Follicular | 16 | 2018 | 70 | 3.660 |
Why?
|
Stem Cell Transplantation | 20 | 2019 | 183 | 3.410 |
Why?
|
Melphalan | 19 | 2020 | 97 | 3.380 |
Why?
|
Fetal Blood | 14 | 2023 | 90 | 3.280 |
Why?
|
Unrelated Donors | 12 | 2020 | 50 | 3.240 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 12 | 2018 | 67 | 3.190 |
Why?
|
Vidarabine | 17 | 2020 | 141 | 3.000 |
Why?
|
Myelodysplastic Syndromes | 19 | 2018 | 345 | 2.870 |
Why?
|
Neoplasm Recurrence, Local | 15 | 2020 | 1305 | 2.800 |
Why?
|
Humans | 309 | 2024 | 86281 | 2.560 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 48 | 2023 | 2434 | 2.500 |
Why?
|
Transplantation, Autologous | 49 | 2021 | 328 | 2.400 |
Why?
|
Antibodies, Neoplasm | 9 | 2011 | 84 | 2.260 |
Why?
|
Middle Aged | 171 | 2022 | 24957 | 2.180 |
Why?
|
Adult | 176 | 2023 | 25577 | 2.150 |
Why?
|
Graft Survival | 23 | 2017 | 883 | 2.130 |
Why?
|
Multiple Myeloma | 16 | 2019 | 307 | 2.120 |
Why?
|
Haplotypes | 7 | 2019 | 642 | 2.120 |
Why?
|
HLA Antigens | 12 | 2018 | 232 | 2.080 |
Why?
|
Immunotherapy, Adoptive | 7 | 2023 | 170 | 2.010 |
Why?
|
Transplantation Chimera | 10 | 2016 | 79 | 2.010 |
Why?
|
Leukemia | 18 | 2019 | 318 | 1.980 |
Why?
|
Antibodies, Monoclonal | 15 | 2020 | 1376 | 1.960 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 12 | 2024 | 151 | 1.950 |
Why?
|
Anemia, Sickle Cell | 6 | 2023 | 131 | 1.880 |
Why?
|
Hematopoietic Stem Cell Mobilization | 13 | 2018 | 50 | 1.860 |
Why?
|
Recurrence | 49 | 2017 | 1137 | 1.860 |
Why?
|
Epstein-Barr Virus Infections | 4 | 2021 | 50 | 1.840 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 10 | 2017 | 136 | 1.820 |
Why?
|
Male | 174 | 2023 | 40860 | 1.800 |
Why?
|
Aged | 96 | 2020 | 18353 | 1.740 |
Why?
|
Survival Analysis | 40 | 2017 | 1536 | 1.740 |
Why?
|
Hematopoietic Stem Cells | 15 | 2018 | 292 | 1.710 |
Why?
|
Female | 178 | 2023 | 44405 | 1.690 |
Why?
|
Lymphoproliferative Disorders | 4 | 2019 | 107 | 1.690 |
Why?
|
Chimerism | 6 | 2020 | 37 | 1.680 |
Why?
|
Adenine Nucleotides | 5 | 2016 | 63 | 1.670 |
Why?
|
Arabinonucleosides | 5 | 2016 | 39 | 1.660 |
Why?
|
Whole-Body Irradiation | 11 | 2020 | 63 | 1.660 |
Why?
|
Hodgkin Disease | 13 | 2014 | 177 | 1.600 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 12 | 2020 | 173 | 1.570 |
Why?
|
Tissue Donors | 19 | 2020 | 462 | 1.570 |
Why?
|
Immunosuppressive Agents | 21 | 2019 | 977 | 1.560 |
Why?
|
Granulocyte Colony-Stimulating Factor | 16 | 2021 | 165 | 1.540 |
Why?
|
Myeloablative Agonists | 10 | 2019 | 34 | 1.530 |
Why?
|
Salvage Therapy | 17 | 2021 | 232 | 1.490 |
Why?
|
Histocompatibility Testing | 17 | 2019 | 154 | 1.450 |
Why?
|
Treatment Outcome | 72 | 2020 | 7949 | 1.430 |
Why?
|
Cryopreservation | 5 | 2018 | 68 | 1.430 |
Why?
|
Central Nervous System Neoplasms | 5 | 2019 | 81 | 1.380 |
Why?
|
Antibodies, Monoclonal, Humanized | 15 | 2021 | 929 | 1.380 |
Why?
|
Antigens, CD34 | 14 | 2018 | 158 | 1.340 |
Why?
|
Neutropenia | 10 | 2020 | 215 | 1.330 |
Why?
|
Cytomegalovirus Infections | 6 | 2020 | 144 | 1.330 |
Why?
|
Viremia | 3 | 2021 | 54 | 1.300 |
Why?
|
Virus Activation | 3 | 2019 | 41 | 1.260 |
Why?
|
Busulfan | 12 | 2020 | 39 | 1.220 |
Why?
|
Lymphocyte Depletion | 9 | 2017 | 97 | 1.220 |
Why?
|
Young Adult | 41 | 2019 | 5961 | 1.200 |
Why?
|
Remission Induction | 27 | 2020 | 722 | 1.200 |
Why?
|
Allografts | 12 | 2021 | 172 | 1.160 |
Why?
|
Disease-Free Survival | 35 | 2019 | 1203 | 1.140 |
Why?
|
Alemtuzumab | 13 | 2020 | 83 | 1.140 |
Why?
|
Primary Myelofibrosis | 4 | 2016 | 55 | 1.130 |
Why?
|
Adolescent | 66 | 2021 | 8968 | 1.100 |
Why?
|
Rituximab | 8 | 2019 | 116 | 1.100 |
Why?
|
Survival Rate | 30 | 2019 | 1856 | 1.060 |
Why?
|
Cyclophosphamide | 16 | 2023 | 299 | 1.020 |
Why?
|
Antineoplastic Agents | 15 | 2020 | 2351 | 1.000 |
Why?
|
Leukemia, Myeloid | 5 | 2016 | 249 | 0.990 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2023 | 1 | 0.960 |
Why?
|
Combined Modality Therapy | 35 | 2020 | 1680 | 0.940 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2023 | 369 | 0.920 |
Why?
|
Photopheresis | 4 | 2017 | 12 | 0.900 |
Why?
|
Antineoplastic Agents, Alkylating | 7 | 2006 | 138 | 0.900 |
Why?
|
Prognosis | 27 | 2020 | 3669 | 0.880 |
Why?
|
Graft vs Tumor Effect | 4 | 2011 | 25 | 0.870 |
Why?
|
Lymphoma, T-Cell, Peripheral | 4 | 2023 | 27 | 0.860 |
Why?
|
Graft vs Leukemia Effect | 3 | 2013 | 11 | 0.850 |
Why?
|
Tacrolimus | 8 | 2019 | 372 | 0.840 |
Why?
|
Transplant Recipients | 6 | 2021 | 120 | 0.820 |
Why?
|
Retrospective Studies | 35 | 2023 | 8431 | 0.770 |
Why?
|
Premedication | 5 | 2017 | 54 | 0.740 |
Why?
|
Thrombotic Microangiopathies | 4 | 2022 | 21 | 0.730 |
Why?
|
Haploidy | 2 | 2016 | 31 | 0.720 |
Why?
|
Antineoplastic Agents, Immunological | 2 | 2019 | 185 | 0.700 |
Why?
|
Acute Kidney Injury | 2 | 2014 | 294 | 0.680 |
Why?
|
Risk Factors | 23 | 2019 | 5397 | 0.660 |
Why?
|
Incidence | 13 | 2019 | 1568 | 0.660 |
Why?
|
Cyclosporine | 5 | 2012 | 234 | 0.650 |
Why?
|
Infusion Pumps | 1 | 2017 | 25 | 0.640 |
Why?
|
Antimetabolites, Antineoplastic | 5 | 2016 | 236 | 0.630 |
Why?
|
Kidney Failure, Chronic | 1 | 2023 | 509 | 0.630 |
Why?
|
Herpesvirus 4, Human | 3 | 2021 | 114 | 0.630 |
Why?
|
Lymphocyte Transfusion | 5 | 2011 | 41 | 0.630 |
Why?
|
Thrombocytopenia | 8 | 2020 | 183 | 0.630 |
Why?
|
Regenerative Medicine | 2 | 2014 | 23 | 0.620 |
Why?
|
Neutrophils | 5 | 2019 | 306 | 0.600 |
Why?
|
Graft Rejection | 6 | 2017 | 1064 | 0.590 |
Why?
|
Ganciclovir | 4 | 2006 | 49 | 0.580 |
Why?
|
Antilymphocyte Serum | 2 | 2021 | 71 | 0.570 |
Why?
|
Roseolovirus Infections | 1 | 2016 | 7 | 0.570 |
Why?
|
Kidney Transplantation | 1 | 2023 | 846 | 0.560 |
Why?
|
Herpesvirus 6, Human | 1 | 2016 | 19 | 0.560 |
Why?
|
Radiation Dosage | 1 | 2017 | 227 | 0.550 |
Why?
|
T-Lymphocytes | 8 | 2023 | 1195 | 0.550 |
Why?
|
Piperazines | 3 | 2020 | 272 | 0.550 |
Why?
|
Hepatic Veno-Occlusive Disease | 4 | 2018 | 19 | 0.540 |
Why?
|
Hematopoiesis | 7 | 2016 | 163 | 0.540 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2019 | 589 | 0.530 |
Why?
|
Acute Disease | 17 | 2016 | 824 | 0.530 |
Why?
|
Interleukin-2 | 6 | 2010 | 249 | 0.520 |
Why?
|
Histocompatibility | 6 | 2016 | 71 | 0.520 |
Why?
|
Follow-Up Studies | 19 | 2019 | 3616 | 0.510 |
Why?
|
Time Factors | 16 | 2018 | 5198 | 0.500 |
Why?
|
Protein Kinase Inhibitors | 3 | 2019 | 589 | 0.500 |
Why?
|
Amino Acid Substitution | 2 | 2016 | 339 | 0.490 |
Why?
|
Pyrimidines | 3 | 2019 | 370 | 0.490 |
Why?
|
Acyclovir | 2 | 2006 | 107 | 0.490 |
Why?
|
Antiviral Agents | 5 | 2020 | 508 | 0.480 |
Why?
|
Desensitization, Immunologic | 1 | 2014 | 36 | 0.480 |
Why?
|
Lymphopoiesis | 1 | 2014 | 48 | 0.480 |
Why?
|
Mycophenolic Acid | 5 | 2019 | 87 | 0.470 |
Why?
|
Skin Diseases | 2 | 2012 | 166 | 0.470 |
Why?
|
Prospective Studies | 16 | 2020 | 4194 | 0.470 |
Why?
|
Thalidomide | 4 | 2017 | 54 | 0.470 |
Why?
|
Bone Marrow Diseases | 2 | 2013 | 40 | 0.460 |
Why?
|
Tomography, X-Ray Computed | 2 | 2023 | 2594 | 0.460 |
Why?
|
Ferritins | 1 | 2013 | 29 | 0.450 |
Why?
|
Anemia, Aplastic | 3 | 2006 | 30 | 0.440 |
Why?
|
Donor Selection | 1 | 2013 | 67 | 0.430 |
Why?
|
Heterocyclic Compounds | 4 | 2018 | 17 | 0.430 |
Why?
|
Clinical Trials as Topic | 10 | 2018 | 1168 | 0.420 |
Why?
|
Self Report | 2 | 2012 | 287 | 0.410 |
Why?
|
Transplantation, Haploidentical | 4 | 2019 | 27 | 0.410 |
Why?
|
Age Factors | 9 | 2018 | 1842 | 0.410 |
Why?
|
Leukocyte Transfusion | 2 | 2010 | 15 | 0.400 |
Why?
|
Decision Trees | 1 | 2011 | 63 | 0.390 |
Why?
|
Myasthenia Gravis | 1 | 2011 | 83 | 0.390 |
Why?
|
Fatal Outcome | 5 | 2011 | 293 | 0.390 |
Why?
|
Renal Insufficiency | 1 | 2011 | 114 | 0.380 |
Why?
|
Carmustine | 4 | 2006 | 70 | 0.370 |
Why?
|
Karnofsky Performance Status | 4 | 2009 | 40 | 0.370 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2011 | 203 | 0.360 |
Why?
|
Vidarabine Phosphate | 1 | 2009 | 5 | 0.350 |
Why?
|
Ifosfamide | 5 | 2004 | 49 | 0.350 |
Why?
|
BK Virus | 1 | 2009 | 23 | 0.350 |
Why?
|
Receptors, Antigen, T-Cell | 4 | 2023 | 371 | 0.350 |
Why?
|
Mediastinal Neoplasms | 2 | 2001 | 46 | 0.350 |
Why?
|
Polyomavirus Infections | 1 | 2009 | 28 | 0.350 |
Why?
|
B-Lymphocytes | 1 | 2014 | 724 | 0.350 |
Why?
|
Bacteremia | 3 | 2021 | 99 | 0.350 |
Why?
|
Hematuria | 1 | 2009 | 49 | 0.350 |
Why?
|
Tumor Virus Infections | 1 | 2009 | 81 | 0.340 |
Why?
|
Patient Selection | 7 | 2007 | 685 | 0.340 |
Why?
|
Leukemia, Lymphoid | 2 | 2012 | 72 | 0.340 |
Why?
|
Pneumonia | 2 | 2010 | 178 | 0.340 |
Why?
|
Lymphoma, B-Cell | 2 | 2001 | 103 | 0.330 |
Why?
|
Interleukin-6 | 2 | 2008 | 255 | 0.330 |
Why?
|
Lymphocyte Count | 3 | 2021 | 94 | 0.330 |
Why?
|
Alleles | 5 | 2016 | 1127 | 0.330 |
Why?
|
Thiotepa | 7 | 2003 | 32 | 0.330 |
Why?
|
Renal Dialysis | 1 | 2011 | 354 | 0.320 |
Why?
|
Calcineurin Inhibitors | 2 | 2011 | 54 | 0.320 |
Why?
|
Fever | 2 | 2020 | 125 | 0.320 |
Why?
|
C-Reactive Protein | 1 | 2008 | 190 | 0.310 |
Why?
|
Imatinib Mesylate | 3 | 2020 | 126 | 0.310 |
Why?
|
Mycoses | 1 | 2007 | 46 | 0.300 |
Why?
|
Dendritic Cells | 2 | 2009 | 424 | 0.300 |
Why?
|
Kaplan-Meier Estimate | 5 | 2017 | 859 | 0.300 |
Why?
|
Blood Donors | 3 | 2016 | 26 | 0.290 |
Why?
|
Dacarbazine | 2 | 2007 | 102 | 0.290 |
Why?
|
Siblings | 8 | 2014 | 111 | 0.290 |
Why?
|
Drug Therapy, Combination | 9 | 2019 | 893 | 0.290 |
Why?
|
Respiratory Tract Infections | 2 | 2018 | 104 | 0.280 |
Why?
|
Child | 21 | 2018 | 6913 | 0.280 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 6 | 2011 | 78 | 0.280 |
Why?
|
Graft vs Host Reaction | 3 | 2009 | 15 | 0.280 |
Why?
|
Mortality | 3 | 2016 | 148 | 0.270 |
Why?
|
Kidney Diseases | 2 | 2009 | 418 | 0.270 |
Why?
|
Valine | 1 | 2006 | 69 | 0.270 |
Why?
|
Isoantibodies | 2 | 2018 | 114 | 0.270 |
Why?
|
Blood Cell Count | 6 | 2016 | 79 | 0.260 |
Why?
|
Postoperative Complications | 3 | 2016 | 2183 | 0.260 |
Why?
|
Sarcoma | 1 | 2007 | 211 | 0.260 |
Why?
|
Etoposide | 9 | 2004 | 196 | 0.260 |
Why?
|
Carcinoma, Renal Cell | 2 | 2006 | 425 | 0.250 |
Why?
|
Methotrexate | 4 | 2019 | 249 | 0.250 |
Why?
|
Mannose-Binding Protein-Associated Serine Proteases | 2 | 2022 | 2 | 0.250 |
Why?
|
Cytarabine | 7 | 2013 | 218 | 0.250 |
Why?
|
Vaccination | 2 | 2022 | 253 | 0.240 |
Why?
|
Glioblastoma | 1 | 2006 | 254 | 0.240 |
Why?
|
Microvessels | 2 | 2022 | 70 | 0.240 |
Why?
|
Immunotherapy | 4 | 2020 | 627 | 0.240 |
Why?
|
Dose-Response Relationship, Drug | 12 | 2013 | 1958 | 0.230 |
Why?
|
Lymphoma, Mantle-Cell | 3 | 2020 | 35 | 0.230 |
Why?
|
Vancomycin | 3 | 2020 | 72 | 0.230 |
Why?
|
Ascorbic Acid | 1 | 2003 | 37 | 0.230 |
Why?
|
Burkitt Lymphoma | 1 | 2003 | 31 | 0.220 |
Why?
|
Levofloxacin | 2 | 2021 | 7 | 0.220 |
Why?
|
Oxides | 1 | 2003 | 43 | 0.220 |
Why?
|
Arsenicals | 1 | 2003 | 48 | 0.220 |
Why?
|
Thorax | 1 | 2023 | 75 | 0.220 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2022 | 40 | 0.210 |
Why?
|
Disease Progression | 7 | 2016 | 1531 | 0.210 |
Why?
|
Geriatric Assessment | 2 | 2014 | 166 | 0.210 |
Why?
|
HIV-1 | 1 | 2023 | 163 | 0.210 |
Why?
|
Leukocyte Count | 4 | 2019 | 220 | 0.210 |
Why?
|
Medical Oncology | 2 | 2020 | 357 | 0.210 |
Why?
|
Bendamustine Hydrochloride | 2 | 2019 | 8 | 0.210 |
Why?
|
Child, Preschool | 9 | 2018 | 3608 | 0.210 |
Why?
|
Pregnancy Complications, Hematologic | 2 | 1991 | 14 | 0.200 |
Why?
|
Aged, 80 and over | 12 | 2018 | 6481 | 0.200 |
Why?
|
Antioxidants | 1 | 2003 | 223 | 0.200 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2019 | 425 | 0.200 |
Why?
|
Gram-Positive Bacterial Infections | 2 | 2014 | 47 | 0.200 |
Why?
|
Bone Marrow | 8 | 2022 | 434 | 0.200 |
Why?
|
Cell Survival | 3 | 2019 | 966 | 0.200 |
Why?
|
Registries | 8 | 2009 | 702 | 0.200 |
Why?
|
Precision Medicine | 2 | 2019 | 394 | 0.200 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2019 | 556 | 0.200 |
Why?
|
Splenomegaly | 2 | 2016 | 27 | 0.200 |
Why?
|
Bortezomib | 2 | 2018 | 75 | 0.200 |
Why?
|
Oncology Service, Hospital | 1 | 2020 | 6 | 0.190 |
Why?
|
Dibenzothiepins | 1 | 2020 | 1 | 0.190 |
Why?
|
Prednisone | 4 | 2023 | 255 | 0.190 |
Why?
|
Trophoblastic Neoplasms | 2 | 1997 | 5 | 0.190 |
Why?
|
Anti-Bacterial Agents | 3 | 2021 | 739 | 0.190 |
Why?
|
Lymphopenia | 1 | 2020 | 28 | 0.190 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2020 | 27 | 0.190 |
Why?
|
Length of Stay | 2 | 2017 | 697 | 0.190 |
Why?
|
Risk | 5 | 2013 | 673 | 0.190 |
Why?
|
Biomarkers, Tumor | 1 | 2008 | 1461 | 0.190 |
Why?
|
Enzyme Inhibitors | 3 | 2020 | 632 | 0.190 |
Why?
|
Oseltamivir | 1 | 2020 | 20 | 0.190 |
Why?
|
Hematology | 1 | 2020 | 29 | 0.190 |
Why?
|
Adult Stem Cells | 2 | 2011 | 30 | 0.190 |
Why?
|
Adenoviridae | 1 | 2021 | 345 | 0.190 |
Why?
|
Kidney Neoplasms | 1 | 2006 | 620 | 0.190 |
Why?
|
Morpholines | 1 | 2020 | 65 | 0.180 |
Why?
|
Pyridones | 1 | 2020 | 51 | 0.180 |
Why?
|
Triazines | 1 | 2020 | 47 | 0.180 |
Why?
|
Blood Platelets | 2 | 2018 | 149 | 0.180 |
Why?
|
Janus Kinase 2 | 2 | 2019 | 57 | 0.180 |
Why?
|
Comorbidity | 3 | 2016 | 943 | 0.180 |
Why?
|
Freedom | 1 | 2019 | 18 | 0.180 |
Why?
|
Guidelines as Topic | 1 | 2020 | 162 | 0.180 |
Why?
|
Janus Kinase 3 | 1 | 2019 | 9 | 0.180 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2019 | 71 | 0.180 |
Why?
|
Leukemia, Prolymphocytic, T-Cell | 1 | 2019 | 4 | 0.180 |
Why?
|
Pilot Projects | 7 | 2012 | 837 | 0.180 |
Why?
|
Familial Mediterranean Fever | 1 | 2019 | 4 | 0.170 |
Why?
|
Blood Preservation | 2 | 2015 | 10 | 0.170 |
Why?
|
New York | 1 | 2019 | 69 | 0.170 |
Why?
|
Enterobacteriaceae | 1 | 2018 | 21 | 0.170 |
Why?
|
Administration, Intravenous | 2 | 2015 | 50 | 0.170 |
Why?
|
Enterobacteriaceae Infections | 1 | 2018 | 22 | 0.170 |
Why?
|
Motivation | 1 | 2021 | 287 | 0.170 |
Why?
|
Proportional Hazards Models | 6 | 2009 | 857 | 0.170 |
Why?
|
Cryoprotective Agents | 1 | 2018 | 8 | 0.170 |
Why?
|
Coronavirus | 1 | 2018 | 19 | 0.160 |
Why?
|
Dimethyl Sulfoxide | 1 | 2018 | 38 | 0.160 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2018 | 66 | 0.160 |
Why?
|
Mycobacterium avium Complex | 1 | 2018 | 6 | 0.160 |
Why?
|
Organ Transplantation | 2 | 2014 | 263 | 0.160 |
Why?
|
Granuloma, Plasma Cell | 1 | 2018 | 9 | 0.160 |
Why?
|
Multivariate Analysis | 10 | 2013 | 997 | 0.160 |
Why?
|
Blood Component Removal | 4 | 2015 | 24 | 0.160 |
Why?
|
Pyrazoles | 1 | 2019 | 153 | 0.160 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 2018 | 24 | 0.160 |
Why?
|
Pyrroles | 1 | 2019 | 184 | 0.160 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2019 | 458 | 0.160 |
Why?
|
Recovery of Function | 1 | 2019 | 272 | 0.160 |
Why?
|
Hydroxyurea | 1 | 2018 | 239 | 0.160 |
Why?
|
Eukaryotic Initiation Factor-4E | 1 | 2017 | 16 | 0.150 |
Why?
|
Antigens, CD19 | 2 | 2022 | 39 | 0.150 |
Why?
|
Piperidines | 1 | 2019 | 181 | 0.150 |
Why?
|
L-Lactate Dehydrogenase | 2 | 2010 | 68 | 0.150 |
Why?
|
Endothelial Cells | 1 | 2020 | 427 | 0.150 |
Why?
|
Treatment Failure | 3 | 2010 | 284 | 0.150 |
Why?
|
Influenza, Human | 1 | 2020 | 329 | 0.150 |
Why?
|
Ribavirin | 1 | 2017 | 57 | 0.150 |
Why?
|
Lymphocyte Subsets | 2 | 2013 | 64 | 0.150 |
Why?
|
Lung | 1 | 2023 | 1167 | 0.140 |
Why?
|
Azacitidine | 3 | 2023 | 137 | 0.140 |
Why?
|
Mastocytosis | 1 | 2016 | 13 | 0.140 |
Why?
|
Tuberculosis | 1 | 2018 | 108 | 0.140 |
Why?
|
Respirovirus | 1 | 2016 | 3 | 0.140 |
Why?
|
Lactate Dehydrogenases | 1 | 2016 | 1 | 0.140 |
Why?
|
Paramyxoviridae Infections | 1 | 2016 | 4 | 0.140 |
Why?
|
Area Under Curve | 2 | 2014 | 334 | 0.140 |
Why?
|
Mice | 5 | 2023 | 11313 | 0.140 |
Why?
|
Cohort Studies | 6 | 2014 | 2759 | 0.140 |
Why?
|
Blood Component Transfusion | 1 | 2015 | 13 | 0.140 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 145 | 0.140 |
Why?
|
Genotype | 2 | 2019 | 1850 | 0.140 |
Why?
|
Blood Transfusion, Autologous | 2 | 2011 | 16 | 0.140 |
Why?
|
Mutation | 3 | 2019 | 3952 | 0.140 |
Why?
|
Living Donors | 2 | 2009 | 339 | 0.140 |
Why?
|
Picornaviridae Infections | 1 | 2015 | 7 | 0.140 |
Why?
|
Injections, Subcutaneous | 1 | 2015 | 117 | 0.140 |
Why?
|
Rhinovirus | 1 | 2015 | 25 | 0.140 |
Why?
|
Mycobacterium tuberculosis | 1 | 2018 | 184 | 0.130 |
Why?
|
Toxoplasmosis | 1 | 2016 | 64 | 0.130 |
Why?
|
Erythrocytes | 3 | 2015 | 255 | 0.130 |
Why?
|
Cell Lineage | 1 | 2016 | 273 | 0.130 |
Why?
|
Stem Cell Factor | 2 | 2012 | 19 | 0.130 |
Why?
|
Toxoplasma | 1 | 2016 | 108 | 0.130 |
Why?
|
Hydroxyethyl Starch Derivatives | 1 | 2015 | 6 | 0.130 |
Why?
|
DNA Mutational Analysis | 2 | 2016 | 526 | 0.130 |
Why?
|
Dextrans | 1 | 2015 | 77 | 0.130 |
Why?
|
Cause of Death | 5 | 2009 | 277 | 0.130 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 100 | 0.130 |
Why?
|
Chronic Disease | 7 | 2010 | 968 | 0.130 |
Why?
|
Cell Count | 1 | 2015 | 194 | 0.130 |
Why?
|
Thyroid Neoplasms | 1 | 2019 | 406 | 0.130 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2010 | 112 | 0.130 |
Why?
|
Brain Neoplasms | 2 | 1997 | 763 | 0.120 |
Why?
|
HIV Infections | 1 | 2023 | 768 | 0.120 |
Why?
|
Benzylamines | 4 | 2018 | 16 | 0.120 |
Why?
|
Tissue Banks | 1 | 2014 | 16 | 0.120 |
Why?
|
Vancomycin-Resistant Enterococci | 1 | 2014 | 13 | 0.120 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2012 | 182 | 0.120 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 2 | 2001 | 8 | 0.120 |
Why?
|
Neoplasms, Second Primary | 3 | 2012 | 252 | 0.120 |
Why?
|
Kidney Function Tests | 1 | 2014 | 123 | 0.120 |
Why?
|
Recombinant Fusion Proteins | 1 | 2016 | 555 | 0.120 |
Why?
|
Hematologic Diseases | 3 | 2015 | 79 | 0.120 |
Why?
|
Neoplasm, Residual | 4 | 2011 | 162 | 0.120 |
Why?
|
Transplants | 1 | 2014 | 40 | 0.120 |
Why?
|
Genetic Diseases, Inborn | 1 | 2014 | 101 | 0.120 |
Why?
|
Pre-Exposure Prophylaxis | 1 | 2016 | 137 | 0.120 |
Why?
|
Illinois | 2 | 2012 | 461 | 0.120 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2014 | 173 | 0.120 |
Why?
|
Nitrogen Mustard Compounds | 1 | 2013 | 1 | 0.120 |
Why?
|
Biomarkers | 2 | 2019 | 1709 | 0.120 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2014 | 155 | 0.120 |
Why?
|
HLA-DR Antigens | 4 | 2000 | 61 | 0.120 |
Why?
|
Coronavirus Infections | 1 | 2018 | 301 | 0.110 |
Why?
|
Benzamides | 2 | 2011 | 226 | 0.110 |
Why?
|
Immunoglobulin Isotypes | 1 | 2013 | 32 | 0.110 |
Why?
|
Uterine Neoplasms | 1 | 1997 | 225 | 0.110 |
Why?
|
Pneumococcal Vaccines | 1 | 2013 | 28 | 0.110 |
Why?
|
HLA-DP Antigens | 1 | 2013 | 9 | 0.110 |
Why?
|
Interferon-gamma | 2 | 2007 | 444 | 0.110 |
Why?
|
Epothilones | 1 | 2013 | 13 | 0.110 |
Why?
|
Daunorubicin | 1 | 2013 | 78 | 0.110 |
Why?
|
Quality of Life | 3 | 2018 | 1575 | 0.110 |
Why?
|
Severity of Illness Index | 2 | 2020 | 1796 | 0.110 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 1990 | 47 | 0.110 |
Why?
|
Opportunistic Infections | 1 | 2013 | 59 | 0.110 |
Why?
|
Erythroid Precursor Cells | 1 | 2012 | 32 | 0.110 |
Why?
|
Polychondritis, Relapsing | 1 | 1992 | 5 | 0.110 |
Why?
|
Neoplasm Staging | 5 | 2010 | 1932 | 0.110 |
Why?
|
HIV Seropositivity | 1 | 2012 | 49 | 0.110 |
Why?
|
Erythropoietin | 1 | 2012 | 91 | 0.110 |
Why?
|
Virus Diseases | 1 | 2013 | 96 | 0.110 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2012 | 6 | 0.110 |
Why?
|
2-Chloroadenosine | 1 | 2011 | 5 | 0.110 |
Why?
|
Pyridostigmine Bromide | 1 | 2011 | 11 | 0.100 |
Why?
|
Genetic Therapy | 1 | 2014 | 342 | 0.100 |
Why?
|
Paraneoplastic Syndromes, Nervous System | 1 | 2011 | 9 | 0.100 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2011 | 10 | 0.100 |
Why?
|
Polymerase Chain Reaction | 3 | 2016 | 927 | 0.100 |
Why?
|
Deoxyadenosines | 1 | 2011 | 23 | 0.100 |
Why?
|
Animals | 6 | 2023 | 26518 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 3 | 2016 | 645 | 0.100 |
Why?
|
Maximum Tolerated Dose | 2 | 2017 | 270 | 0.100 |
Why?
|
Heparinoids | 1 | 1991 | 4 | 0.100 |
Why?
|
Feasibility Studies | 7 | 2009 | 751 | 0.100 |
Why?
|
Dermatan Sulfate | 1 | 1991 | 9 | 0.100 |
Why?
|
Central Nervous System | 1 | 2022 | 151 | 0.100 |
Why?
|
Heparitin Sulfate | 1 | 1991 | 27 | 0.100 |
Why?
|
Gastrointestinal Microbiome | 1 | 2017 | 451 | 0.100 |
Why?
|
Recombinant Proteins | 11 | 2009 | 1014 | 0.100 |
Why?
|
Glycosaminoglycans | 1 | 1991 | 47 | 0.100 |
Why?
|
Morbidity | 1 | 2011 | 146 | 0.100 |
Why?
|
Chondroitin Sulfates | 1 | 1991 | 43 | 0.100 |
Why?
|
Infant | 3 | 2018 | 3036 | 0.100 |
Why?
|
CD3 Complex | 2 | 2009 | 135 | 0.100 |
Why?
|
Education | 1 | 2011 | 58 | 0.100 |
Why?
|
Metabolic Clearance Rate | 1 | 2010 | 121 | 0.100 |
Why?
|
Pneumonia, Viral | 1 | 2016 | 316 | 0.100 |
Why?
|
Data Collection | 4 | 2009 | 371 | 0.100 |
Why?
|
Peritoneal Neoplasms | 1 | 2012 | 175 | 0.100 |
Why?
|
Random Allocation | 1 | 2011 | 332 | 0.100 |
Why?
|
Nervous System Diseases | 1 | 2011 | 151 | 0.090 |
Why?
|
Heparin | 1 | 1991 | 175 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2010 | 378 | 0.090 |
Why?
|
Drug Combinations | 1 | 2010 | 222 | 0.090 |
Why?
|
Blood Coagulation Disorders | 1 | 1991 | 63 | 0.090 |
Why?
|
Glomerular Filtration Rate | 1 | 2011 | 384 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2006 | 850 | 0.090 |
Why?
|
Myeloid Cells | 1 | 2010 | 97 | 0.090 |
Why?
|
Bone Marrow Purging | 2 | 2006 | 7 | 0.090 |
Why?
|
Nuclear Family | 2 | 2000 | 92 | 0.090 |
Why?
|
Monitoring, Physiologic | 1 | 2011 | 268 | 0.090 |
Why?
|
Congresses as Topic | 1 | 2010 | 116 | 0.090 |
Why?
|
Sirolimus | 1 | 2010 | 169 | 0.090 |
Why?
|
Drug Administration Schedule | 8 | 2013 | 916 | 0.090 |
Why?
|
Diarrhea | 3 | 2020 | 181 | 0.090 |
Why?
|
Research Design | 1 | 2012 | 594 | 0.090 |
Why?
|
Down-Regulation | 1 | 2010 | 504 | 0.080 |
Why?
|
Vancomycin Resistance | 1 | 2008 | 18 | 0.080 |
Why?
|
Enterococcus | 1 | 2008 | 35 | 0.080 |
Why?
|
Age Distribution | 1 | 2009 | 204 | 0.080 |
Why?
|
New York City | 2 | 2020 | 59 | 0.080 |
Why?
|
HLA-DQ Antigens | 2 | 2000 | 52 | 0.080 |
Why?
|
Leukocytosis | 1 | 2008 | 16 | 0.080 |
Why?
|
Antigens, CD | 4 | 2003 | 457 | 0.080 |
Why?
|
Antifungal Agents | 2 | 2007 | 117 | 0.080 |
Why?
|
Predictive Value of Tests | 2 | 2014 | 1671 | 0.080 |
Why?
|
Thrombophilia | 1 | 2008 | 22 | 0.080 |
Why?
|
Creatinine | 1 | 2009 | 337 | 0.080 |
Why?
|
Osteopontin | 1 | 2008 | 47 | 0.080 |
Why?
|
Self Tolerance | 1 | 2007 | 24 | 0.080 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2008 | 107 | 0.080 |
Why?
|
Cisplatin | 4 | 1999 | 612 | 0.080 |
Why?
|
Cell Separation | 4 | 2015 | 196 | 0.080 |
Why?
|
Cardiac Tamponade | 1 | 2007 | 17 | 0.080 |
Why?
|
Cross Infection | 1 | 2008 | 141 | 0.080 |
Why?
|
Administration, Topical | 1 | 2007 | 94 | 0.080 |
Why?
|
Health Status | 1 | 2009 | 360 | 0.070 |
Why?
|
Industry | 1 | 2007 | 16 | 0.070 |
Why?
|
Immunity, Cellular | 1 | 2007 | 177 | 0.070 |
Why?
|
History, 19th Century | 1 | 2007 | 59 | 0.070 |
Why?
|
Filgrastim | 5 | 2009 | 56 | 0.070 |
Why?
|
Liver Diseases | 1 | 2008 | 238 | 0.070 |
Why?
|
Algorithms | 1 | 2015 | 1828 | 0.070 |
Why?
|
Data Interpretation, Statistical | 1 | 2008 | 297 | 0.070 |
Why?
|
Models, Animal | 1 | 2007 | 261 | 0.070 |
Why?
|
Doxorubicin | 2 | 2023 | 289 | 0.070 |
Why?
|
Cytoskeleton | 1 | 2008 | 192 | 0.070 |
Why?
|
Research Support as Topic | 1 | 2007 | 80 | 0.070 |
Why?
|
Immunologic Factors | 2 | 2023 | 170 | 0.070 |
Why?
|
Ethics, Research | 1 | 2007 | 52 | 0.070 |
Why?
|
Hospitals, Special | 1 | 2005 | 7 | 0.070 |
Why?
|
History, 21st Century | 1 | 2007 | 175 | 0.070 |
Why?
|
Intestinal Diseases | 1 | 2006 | 79 | 0.070 |
Why?
|
Pain | 1 | 2008 | 389 | 0.070 |
Why?
|
History, 20th Century | 1 | 2007 | 312 | 0.070 |
Why?
|
Autoimmune Diseases | 1 | 2007 | 241 | 0.070 |
Why?
|
Fatigue | 1 | 2006 | 174 | 0.070 |
Why?
|
Lymphocytes | 1 | 2007 | 461 | 0.060 |
Why?
|
Double-Blind Method | 3 | 2017 | 1822 | 0.060 |
Why?
|
Neoplasm Metastasis | 2 | 2006 | 1056 | 0.060 |
Why?
|
Granulocyte Precursor Cells | 1 | 2004 | 7 | 0.060 |
Why?
|
Actins | 1 | 2008 | 448 | 0.060 |
Why?
|
Cost of Illness | 1 | 2005 | 150 | 0.060 |
Why?
|
Karyopherins | 1 | 2024 | 14 | 0.060 |
Why?
|
Hydrazines | 1 | 2024 | 30 | 0.060 |
Why?
|
Cephalexin | 1 | 2003 | 6 | 0.060 |
Why?
|
Immunocompromised Host | 3 | 2020 | 140 | 0.060 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2024 | 75 | 0.060 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2003 | 16 | 0.060 |
Why?
|
Neoplasms | 2 | 2016 | 2889 | 0.060 |
Why?
|
Pregnancy | 4 | 1997 | 2885 | 0.060 |
Why?
|
Transduction, Genetic | 2 | 2019 | 153 | 0.060 |
Why?
|
Cell Culture Techniques | 1 | 2004 | 187 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2007 | 530 | 0.060 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2024 | 122 | 0.060 |
Why?
|
Vincristine | 1 | 2023 | 111 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2019 | 2267 | 0.060 |
Why?
|
Immunoconjugates | 1 | 2004 | 106 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2013 | 1801 | 0.060 |
Why?
|
Complement Membrane Attack Complex | 1 | 2022 | 20 | 0.050 |
Why?
|
Body Mass Index | 1 | 2006 | 770 | 0.050 |
Why?
|
Cell Division | 2 | 2002 | 696 | 0.050 |
Why?
|
Growth Inhibitors | 1 | 2002 | 41 | 0.050 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2002 | 63 | 0.050 |
Why?
|
Probability | 1 | 2003 | 355 | 0.050 |
Why?
|
Megakaryocytes | 3 | 1992 | 36 | 0.050 |
Why?
|
Antineoplastic Protocols | 1 | 2002 | 9 | 0.050 |
Why?
|
United States | 6 | 2011 | 6637 | 0.050 |
Why?
|
Thrombosis | 1 | 2005 | 296 | 0.050 |
Why?
|
MEDLINE | 1 | 2001 | 8 | 0.050 |
Why?
|
DNA Damage | 1 | 2024 | 362 | 0.050 |
Why?
|
Fluoroquinolones | 1 | 2021 | 22 | 0.050 |
Why?
|
MAP Kinase Signaling System | 1 | 2002 | 192 | 0.050 |
Why?
|
Risk Assessment | 2 | 2016 | 2253 | 0.050 |
Why?
|
Biopsy | 2 | 2018 | 1160 | 0.050 |
Why?
|
Cytogenetics | 1 | 2001 | 27 | 0.050 |
Why?
|
Cell Line, Tumor | 2 | 2024 | 2421 | 0.050 |
Why?
|
Diagnosis, Differential | 2 | 2007 | 1562 | 0.050 |
Why?
|
Mitoxantrone | 2 | 2012 | 68 | 0.050 |
Why?
|
Antibiotic Prophylaxis | 1 | 2021 | 69 | 0.050 |
Why?
|
Cells, Cultured | 5 | 2018 | 2810 | 0.050 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2020 | 33 | 0.050 |
Why?
|
Hematopoietic System | 1 | 2020 | 13 | 0.050 |
Why?
|
Patient Isolation | 1 | 2020 | 11 | 0.050 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2020 | 23 | 0.050 |
Why?
|
Melanoma | 1 | 2005 | 454 | 0.050 |
Why?
|
Family | 2 | 2012 | 311 | 0.050 |
Why?
|
Foscarnet | 2 | 1997 | 12 | 0.050 |
Why?
|
Virus Shedding | 1 | 2020 | 26 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2011 | 70 | 0.050 |
Why?
|
Drug Resistance, Viral | 1 | 2020 | 51 | 0.050 |
Why?
|
Colony-Stimulating Factors | 2 | 1990 | 14 | 0.050 |
Why?
|
Age of Onset | 1 | 2001 | 306 | 0.050 |
Why?
|
Growth Substances | 2 | 1990 | 80 | 0.050 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 415 | 0.040 |
Why?
|
Gentamicins | 1 | 1999 | 19 | 0.040 |
Why?
|
Immune Tolerance | 2 | 2014 | 337 | 0.040 |
Why?
|
Cross Reactions | 1 | 2019 | 106 | 0.040 |
Why?
|
Janus Kinase 1 | 1 | 2019 | 15 | 0.040 |
Why?
|
Deoxycytidine | 2 | 2013 | 237 | 0.040 |
Why?
|
Obesity | 1 | 2006 | 962 | 0.040 |
Why?
|
Colchicine | 1 | 2019 | 23 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2008 | 1917 | 0.040 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 1 | 2018 | 20 | 0.040 |
Why?
|
Multilocus Sequence Typing | 1 | 2018 | 11 | 0.040 |
Why?
|
Bacterial Typing Techniques | 1 | 2018 | 28 | 0.040 |
Why?
|
Granulocytes | 2 | 2015 | 37 | 0.040 |
Why?
|
Feces | 1 | 2020 | 316 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 1 | 2001 | 237 | 0.040 |
Why?
|
Nitriles | 1 | 2019 | 145 | 0.040 |
Why?
|
Symptom Assessment | 1 | 2019 | 65 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2002 | 683 | 0.040 |
Why?
|
Drug Resistance, Bacterial | 1 | 2018 | 71 | 0.040 |
Why?
|
Antisickling Agents | 1 | 2018 | 4 | 0.040 |
Why?
|
Microbial Sensitivity Tests | 1 | 2018 | 142 | 0.040 |
Why?
|
beta-Lactamases | 1 | 2018 | 51 | 0.040 |
Why?
|
Tumor Lysis Syndrome | 1 | 2018 | 9 | 0.040 |
Why?
|
HeLa Cells | 1 | 2019 | 498 | 0.040 |
Why?
|
Febrile Neutropenia | 1 | 2018 | 14 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2002 | 694 | 0.040 |
Why?
|
RNA, Messenger | 1 | 2024 | 1975 | 0.040 |
Why?
|
Antitubercular Agents | 1 | 2018 | 52 | 0.040 |
Why?
|
Signal Transduction | 2 | 2012 | 3233 | 0.040 |
Why?
|
Colony-Forming Units Assay | 2 | 2015 | 40 | 0.040 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2017 | 14 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 1 | 1999 | 302 | 0.040 |
Why?
|
Telemedicine | 1 | 2020 | 168 | 0.040 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 1030 | 0.040 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2017 | 22 | 0.040 |
Why?
|
Cell Differentiation | 4 | 2012 | 1456 | 0.040 |
Why?
|
HEK293 Cells | 1 | 2019 | 615 | 0.040 |
Why?
|
Kinetics | 1 | 2020 | 1513 | 0.040 |
Why?
|
Placebos | 1 | 2017 | 218 | 0.040 |
Why?
|
Genetic Association Studies | 1 | 2019 | 294 | 0.040 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 1047 | 0.040 |
Why?
|
Vascular Diseases | 1 | 2018 | 119 | 0.040 |
Why?
|
Hemorrhage | 2 | 1995 | 265 | 0.040 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2017 | 241 | 0.040 |
Why?
|
Aspergillosis | 1 | 1997 | 41 | 0.040 |
Why?
|
Communication | 1 | 2020 | 438 | 0.040 |
Why?
|
Parasitemia | 1 | 2016 | 6 | 0.040 |
Why?
|
Gastrointestinal Tract | 1 | 2018 | 191 | 0.040 |
Why?
|
Unsupervised Machine Learning | 1 | 2016 | 7 | 0.040 |
Why?
|
Dioxygenases | 1 | 2016 | 74 | 0.040 |
Why?
|
Epidemiological Monitoring | 1 | 2016 | 39 | 0.040 |
Why?
|
Carboprost | 1 | 1995 | 2 | 0.040 |
Why?
|
Cystitis | 1 | 1995 | 13 | 0.030 |
Why?
|
Phosphorylation | 2 | 2012 | 1101 | 0.030 |
Why?
|
Sequence Homology | 1 | 2015 | 28 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2016 | 131 | 0.030 |
Why?
|
Decision Making | 1 | 2001 | 641 | 0.030 |
Why?
|
Breast Neoplasms | 2 | 2001 | 2881 | 0.030 |
Why?
|
Viral Structural Proteins | 1 | 2015 | 19 | 0.030 |
Why?
|
Platelet Transfusion | 1 | 1995 | 14 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2015 | 679 | 0.030 |
Why?
|
Anti-HIV Agents | 1 | 2018 | 149 | 0.030 |
Why?
|
Disease Management | 1 | 2018 | 327 | 0.030 |
Why?
|
Complementarity Determining Regions | 1 | 2015 | 24 | 0.030 |
Why?
|
Viral Load | 1 | 2016 | 148 | 0.030 |
Why?
|
Molecular Epidemiology | 1 | 2015 | 53 | 0.030 |
Why?
|
Stem Cells | 1 | 1997 | 350 | 0.030 |
Why?
|
Bone Neoplasms | 1 | 1998 | 322 | 0.030 |
Why?
|
Isotonic Solutions | 1 | 2015 | 17 | 0.030 |
Why?
|
Bone Marrow Cells | 3 | 1990 | 253 | 0.030 |
Why?
|
Electrolytes | 1 | 2015 | 52 | 0.030 |
Why?
|
Osmolar Concentration | 1 | 2015 | 181 | 0.030 |
Why?
|
Hemolysis | 1 | 2015 | 61 | 0.030 |
Why?
|
Citric Acid | 1 | 2015 | 38 | 0.030 |
Why?
|
Chicago | 2 | 2010 | 1377 | 0.030 |
Why?
|
Platelet Count | 2 | 1992 | 92 | 0.030 |
Why?
|
Transcription Factors | 1 | 2002 | 1555 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2015 | 155 | 0.030 |
Why?
|
Drug Synergism | 1 | 2015 | 303 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2012 | 1571 | 0.030 |
Why?
|
Consensus | 1 | 2016 | 333 | 0.030 |
Why?
|
Interferon Type I | 1 | 1995 | 175 | 0.030 |
Why?
|
Sinusitis | 1 | 1997 | 209 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2015 | 369 | 0.030 |
Why?
|
Pedigree | 1 | 2016 | 966 | 0.030 |
Why?
|
Pandemics | 1 | 2020 | 739 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 1994 | 76 | 0.030 |
Why?
|
Testicular Neoplasms | 1 | 2015 | 104 | 0.030 |
Why?
|
Biological Factors | 2 | 1990 | 18 | 0.030 |
Why?
|
Infusions, Intravenous | 3 | 1999 | 429 | 0.030 |
Why?
|
Boronic Acids | 1 | 2013 | 54 | 0.030 |
Why?
|
Pyrazines | 1 | 2013 | 84 | 0.030 |
Why?
|
Administration, Oral | 1 | 2014 | 683 | 0.030 |
Why?
|
Blood Grouping and Crossmatching | 1 | 2012 | 14 | 0.030 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 44 | 0.030 |
Why?
|
Telomerase | 1 | 2012 | 55 | 0.030 |
Why?
|
Nutritional Status | 1 | 2012 | 83 | 0.030 |
Why?
|
Logistic Models | 1 | 2016 | 1184 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2013 | 153 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2014 | 134 | 0.030 |
Why?
|
Receptors, CXCR4 | 1 | 2012 | 44 | 0.030 |
Why?
|
Frail Elderly | 1 | 2012 | 71 | 0.030 |
Why?
|
Maintenance Chemotherapy | 1 | 2012 | 76 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2015 | 853 | 0.030 |
Why?
|
Glucose | 1 | 2015 | 637 | 0.030 |
Why?
|
Life Tables | 2 | 2006 | 48 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2012 | 262 | 0.030 |
Why?
|
Liver Neoplasms | 1 | 1998 | 731 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2012 | 202 | 0.030 |
Why?
|
Lupus Coagulation Inhibitor | 1 | 1991 | 8 | 0.030 |
Why?
|
Mental Health | 1 | 2012 | 160 | 0.030 |
Why?
|
Models, Biological | 2 | 2009 | 1748 | 0.030 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2012 | 121 | 0.030 |
Why?
|
Labor, Obstetric | 1 | 1991 | 46 | 0.030 |
Why?
|
Blood Coagulation Factors | 1 | 1991 | 20 | 0.030 |
Why?
|
Parvoviridae | 1 | 1990 | 3 | 0.020 |
Why?
|
Hemoglobins | 1 | 1991 | 179 | 0.020 |
Why?
|
Preleukemia | 1 | 1990 | 10 | 0.020 |
Why?
|
Mucositis | 1 | 2010 | 17 | 0.020 |
Why?
|
Reticulocytes | 1 | 1990 | 25 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2011 | 156 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2012 | 386 | 0.020 |
Why?
|
Immunomodulation | 1 | 2010 | 55 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2016 | 1208 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2011 | 138 | 0.020 |
Why?
|
Group Processes | 1 | 2010 | 31 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2011 | 399 | 0.020 |
Why?
|
Phylogeny | 1 | 2015 | 1136 | 0.020 |
Why?
|
Rationalization | 1 | 2009 | 1 | 0.020 |
Why?
|
Interleukins | 1 | 1990 | 132 | 0.020 |
Why?
|
Erythrocyte Transfusion | 1 | 1990 | 60 | 0.020 |
Why?
|
Methods | 1 | 2009 | 152 | 0.020 |
Why?
|
Cancer Vaccines | 1 | 2011 | 156 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2011 | 263 | 0.020 |
Why?
|
Calibration | 1 | 2009 | 99 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2010 | 162 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2011 | 329 | 0.020 |
Why?
|
Sclerosing Solutions | 1 | 1988 | 5 | 0.020 |
Why?
|
Galvanic Skin Response | 1 | 2008 | 12 | 0.020 |
Why?
|
Esophageal and Gastric Varices | 1 | 1988 | 33 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2009 | 237 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2012 | 532 | 0.020 |
Why?
|
Integrin alpha4 | 1 | 2008 | 11 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2008 | 71 | 0.020 |
Why?
|
Autoantibodies | 1 | 1989 | 267 | 0.020 |
Why?
|
Integrin beta1 | 1 | 2008 | 33 | 0.020 |
Why?
|
Body Weight | 1 | 2009 | 459 | 0.020 |
Why?
|
Hyaluronan Receptors | 1 | 2008 | 36 | 0.020 |
Why?
|
Demography | 1 | 2008 | 177 | 0.020 |
Why?
|
Blast Crisis | 2 | 1999 | 33 | 0.020 |
Why?
|
Leukemic Infiltration | 1 | 2007 | 14 | 0.020 |
Why?
|
Population Surveillance | 1 | 2008 | 219 | 0.020 |
Why?
|
Pericardial Effusion | 1 | 2007 | 19 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 1989 | 456 | 0.020 |
Why?
|
Intellectual Property | 1 | 2007 | 3 | 0.020 |
Why?
|
Steroids | 1 | 2008 | 172 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2010 | 429 | 0.020 |
Why?
|
Vinblastine | 1 | 2007 | 108 | 0.020 |
Why?
|
Bleomycin | 1 | 2007 | 98 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2010 | 1015 | 0.020 |
Why?
|
Liver | 1 | 2012 | 1229 | 0.020 |
Why?
|
Thinness | 1 | 2006 | 43 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2007 | 122 | 0.020 |
Why?
|
Apoptosis | 1 | 2012 | 1678 | 0.020 |
Why?
|
Reoperation | 1 | 2008 | 589 | 0.020 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1988 | 229 | 0.020 |
Why?
|
Monophenol Monooxygenase | 1 | 2005 | 9 | 0.020 |
Why?
|
Carboplatin | 2 | 2001 | 286 | 0.020 |
Why?
|
Respiratory Insufficiency | 1 | 2007 | 149 | 0.020 |
Why?
|
HLA-A2 Antigen | 1 | 2005 | 31 | 0.020 |
Why?
|
Overweight | 1 | 2006 | 118 | 0.020 |
Why?
|
Jurkat Cells | 1 | 2005 | 77 | 0.020 |
Why?
|
Intracranial Thrombosis | 1 | 2005 | 26 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2007 | 363 | 0.020 |
Why?
|
Retroviridae | 1 | 2005 | 78 | 0.020 |
Why?
|
Prevalence | 1 | 2008 | 1239 | 0.020 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2005 | 89 | 0.020 |
Why?
|
Gene Transfer Techniques | 1 | 2005 | 152 | 0.020 |
Why?
|
Warfarin | 1 | 2005 | 103 | 0.020 |
Why?
|
Arterial Occlusive Diseases | 1 | 2005 | 107 | 0.020 |
Why?
|
Immunophenotyping | 2 | 1995 | 211 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2005 | 123 | 0.010 |
Why?
|
Aspirin | 1 | 2005 | 156 | 0.010 |
Why?
|
Motor Activity | 1 | 2006 | 327 | 0.010 |
Why?
|
Genetic Vectors | 1 | 2005 | 438 | 0.010 |
Why?
|
Transplantation, Isogeneic | 1 | 2002 | 39 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2008 | 1918 | 0.010 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 125 | 0.010 |
Why?
|
Echocardiography | 1 | 2007 | 911 | 0.010 |
Why?
|
Forkhead Transcription Factors | 1 | 2002 | 166 | 0.010 |
Why?
|
Isoenzymes | 1 | 2002 | 271 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2002 | 222 | 0.010 |
Why?
|
Infusions, Intraosseous | 1 | 2001 | 4 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2002 | 321 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2002 | 692 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 1040 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2001 | 213 | 0.010 |
Why?
|
Genes, MHC Class II | 1 | 2000 | 30 | 0.010 |
Why?
|
Hearing Disorders | 1 | 1999 | 7 | 0.010 |
Why?
|
Podophyllotoxin | 1 | 1999 | 10 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcr | 1 | 1999 | 7 | 0.010 |
Why?
|
Leukemia, Myeloid, Accelerated Phase | 1 | 1999 | 7 | 0.010 |
Why?
|
Oncogene Proteins | 1 | 1999 | 59 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1997 | 66 | 0.010 |
Why?
|
Idarubicin | 1 | 1997 | 8 | 0.010 |
Why?
|
Serology | 1 | 1997 | 3 | 0.010 |
Why?
|
Cladribine | 1 | 1997 | 35 | 0.010 |
Why?
|
Y Chromosome | 1 | 1997 | 28 | 0.010 |
Why?
|
CD8 Antigens | 1 | 1997 | 82 | 0.010 |
Why?
|
Amphotericin B | 1 | 1997 | 34 | 0.010 |
Why?
|
X Chromosome | 1 | 1997 | 152 | 0.010 |
Why?
|
Pseudomonas Infections | 1 | 1997 | 95 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 1997 | 348 | 0.010 |
Why?
|
Cytokines | 2 | 1990 | 775 | 0.010 |
Why?
|
Administration, Intravesical | 1 | 1995 | 30 | 0.010 |
Why?
|
Thy-1 Antigens | 1 | 1995 | 16 | 0.010 |
Why?
|
Nausea | 1 | 1997 | 175 | 0.010 |
Why?
|
Chimera | 1 | 1995 | 56 | 0.010 |
Why?
|
Regression Analysis | 1 | 1997 | 595 | 0.010 |
Why?
|
Vomiting | 1 | 1997 | 193 | 0.010 |
Why?
|
Immunomagnetic Separation | 1 | 1994 | 8 | 0.010 |
Why?
|
Lung Diseases | 1 | 1994 | 263 | 0.010 |
Why?
|
Thrombopoietin | 1 | 1992 | 12 | 0.010 |
Why?
|
Thymidine | 1 | 1992 | 59 | 0.010 |
Why?
|
Tritium | 1 | 1992 | 133 | 0.010 |
Why?
|
Kidney | 1 | 1997 | 1240 | 0.010 |
Why?
|
Viral Core Proteins | 1 | 1990 | 27 | 0.010 |
Why?
|
Capsid | 1 | 1990 | 34 | 0.010 |
Why?
|
Sialic Acid Binding Ig-like Lectin 3 | 1 | 1990 | 8 | 0.010 |
Why?
|
Lewis X Antigen | 1 | 1990 | 9 | 0.010 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 1990 | 32 | 0.010 |
Why?
|
Leukopenia | 1 | 1990 | 65 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1990 | 256 | 0.010 |
Why?
|
Viral Nonstructural Proteins | 1 | 1990 | 37 | 0.010 |
Why?
|
Antigens, Differentiation | 1 | 1990 | 141 | 0.010 |
Why?
|
Culture Techniques | 1 | 1990 | 91 | 0.010 |
Why?
|
DNA Replication | 1 | 1990 | 164 | 0.010 |
Why?
|
DNA, Viral | 1 | 1990 | 265 | 0.010 |
Why?
|
Antigens, Surface | 1 | 1990 | 101 | 0.010 |
Why?
|
Drug Evaluation | 1 | 1989 | 141 | 0.010 |
Why?
|
Virus Replication | 1 | 1990 | 319 | 0.010 |
Why?
|
Organoplatinum Compounds | 1 | 1989 | 94 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 1990 | 987 | 0.010 |
Why?
|
Periodicity | 1 | 1989 | 119 | 0.010 |
Why?
|
Cell Cycle | 1 | 1990 | 502 | 0.010 |
Why?
|
Esophagoscopy | 1 | 1988 | 87 | 0.000 |
Why?
|
Ovarian Neoplasms | 1 | 1989 | 738 | 0.000 |
Why?
|